MENU
+Compare
ZVRA
Stock ticker: NASDAQ
AS OF
Jul 3 closing price
Price
$9.41
Change
-$0.00 (-0.00%)
Capitalization
532.58M

ZVRA Zevra Therapeutics Forecast, Technical & Fundamental Analysis

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options... Show more

ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ZVRA with price predictions
Jul 03, 2025

ZVRA sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for ZVRA moved above the 200-day moving average on June 20, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 72 cases where ZVRA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on ZVRA as a result. In of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZVRA advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 160 cases where ZVRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ZVRA moved out of overbought territory on June 13, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for ZVRA turned negative on June 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZVRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ZVRA broke above its upper Bollinger Band on July 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZVRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.987) is normal, around the industry mean (16.672). P/E Ratio (0.000) is within average values for comparable stocks, (58.456). ZVRA's Projected Growth (PEG Ratio) (10.667) is very high in comparison to the industry average of (2.315). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (11.834) is also within normal values, averaging (269.644).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ZVRA is expected to report earnings to rise 20.83% to -7 cents per share on August 19

Zevra Therapeutics ZVRA Stock Earnings Reports
Q2'25
Est.
$-0.07
Q1'25
Beat
by $0.18
Q4'24
Missed
by $0.27
Q3'24
Missed
by $0.28
Q2'24
Missed
by $0.02
The last earnings report on May 13 showed earnings per share of -5 cents, beating the estimate of -23 cents. With 3.17K shares outstanding, the current market capitalization sits at 532.58M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1180 Celebration Boulevard
Phone
+1 321 939-3416
Employees
69
Web
https://www.zevra.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HQISX21.45N/A
N/A
Hartford Equity Income R4
DNLRX62.42N/A
N/A
BNY Mellon Active MidCap I
GSPUX42.20N/A
N/A
Goldman Sachs Large Cap Equity R6
GIDUX8.01N/A
N/A
Goldman Sachs Intl Eq Div & Prem R6
PETZX14.51N/A
N/A
Gabelli Pet Parents'™

ZVRA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with CRNX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZVRA
1D Price
Change %
ZVRA100%
+3.51%
CRNX - ZVRA
40%
Loosely correlated
+1.22%
ATXS - ZVRA
39%
Loosely correlated
+1.40%
QURE - ZVRA
38%
Loosely correlated
+0.98%
DNTH - ZVRA
37%
Loosely correlated
+2.56%
EYPT - ZVRA
37%
Loosely correlated
+0.62%
More